Detailed Information
Cited 54 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naive EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
- Authors
- Bauml, J[Bauml, Joshua]; Cho, BC[Cho, Byoung Chul]; Park, K[Park, Keunchil]; Lee, KH[Lee, Ki Hyeong]; Cho, EK[Cho, Eun Kyung]; Kim, DW[Kim, Dong-Wan]; Kim, SW[Kim, Sang-We]; Haura, EB[Haura, Eric B.]; Sabari, JK[Sabari, Joshua K.]; Sanborn, RE[Sanborn, Rachel E.]; Nagasaka, M[Nagasaka, Misako]; Ou, SHI[Ou, Sai-Hong Ignatius]; Minchom, AR[Minchom, Anna Rachel]; Gomez, JE[Gomez, Jorge E.]; Curtin, JC[Curtin, Joshua C.]; Gao, G[Gao, Grace]; Roshak, A[Roshak, Amy]; Thayu, M[Thayu, Meena]; Knoblauch, RE[Knoblauch, Roland Elmar]; Spira, AI[Spira, Alexander I.]
- Issue Date
- 20-May-2021
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.39, no.15
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 39
- Number
- 15
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.